Action BGLC BIONEXUS GENE LAB CORP.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues BioNexus Gene Lab Corp.

Actions

BGLC

US0906282076

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/04/2024 		Varia. 5j. Varia. 1 janv.
0,5935 USD +0,15% Graphique intraday de BioNexus Gene Lab Corp. -1,05% +11,98%
16/04 BioNexus Gene Lab Corp. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI
29/02 BioNexus Gene Lab Corp. fournit des informations à ses actionnaires CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare
BioNexus Gene Lab : Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare - Form 8-K
BioNexus Gene Lab Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
BioNexus Gene Lab : Submission of Matters to a Vote of Security Holders - Form 8-K
BioNexus Gene Lab Corp. Provides Information to Shareholders
Certain Common Stock of BioNexus Gene Lab Corp. are subject to a Lock-Up Agreement Ending on 18-JAN-2024.
Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab Corp
BioNexus Gene Lab Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Bionexus Gene Lab Corp. Announces Resignation of Wei Li Leong as Chief Financial Officer
BioNexus Gene Lab Names Chi Yuen Leong as CEO
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive Officer
BioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as A Director
BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive Officer
BioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Board of Directors
BioNexus Gene Lab Corp. Announces Executive Changes
Top Premarket Gainers
BioNexus Gene Lab Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
BioNexus Gene Lab Raises $5.8 Million from Public Share Offering
BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market
BioNexus Gene Lab Corp.(NasdaqCM:BGLC) added to NASDAQ Composite Index
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BGLC
  4. Actualités BioNexus Gene Lab Corp.
  5. Autres langues